After reading these paragraphs, I was intrigued:
Dr. Nicholas J. Gonzalez: "In July 1993, the then
Associate Director for the Cancer Therapy Evaluation Program at the
National Cancer Institute, Dr. Michael Friedman, invited me to present
selected cases from my own practice as part of an NCI effort to evaluate
non-traditional cancer therapies. I prepared for presentation 25 cases
with poor prognosis or terminal illness who had either enjoyed long-term
survival or tumor regression while following my program. After the
session, Dr. Friedman suggested we pursue a pilot study of our methods
in 10 patients suffering inoperable adenocarcinoma of the pancreas,
with survival as the endpoint. Because the standard survival for the
disease is so poor, an effect could be seen in a small number of patients
in a short period of time.
Nestec (the Nestle Corporation)
agreed to fund the trial, which began in January 1994. The study has
been completed and was published in Nutrition and Cancer, June,
1999;33(2). Of 11 patients followed in the trial, eight of
11 suffered stage four disease. Nine of 11 (81%) lived one year, five
of 11 lived two years (45%), and four of 11 lived three years (36%).
Two are alive and well with no signs of disease, one at 3.5 years
and one at 4.5 years. In comparison, in a recent trial of the newly-approved
drug gemcitabine, of 126 patients with pancreatic cancer not a single
patient lived longer than 19 months.
As a result of the pilot study,
the National Cancer Institute approved $1.4 million over five years
for a large scale, randomized clinical trial comparing my nutritional
therapy against gemcitabine in the treatment of inoperable pancreatic
cancer. This study has full FDA approval and is being conducted under
the Department of Oncology and the Department of Surgical Oncology
at Columbia Presbyterian Medical Center in New York. The trial is
the outgrowth of a Congressional hearing last summer encouraging intensive
government evaluation of promising alternative cancer treatments,
and is currently up and running. We are accruing patients right now
for the study, and interested patients can learn more about this study
and its objectives from Michelle Gabay, in the office of Dr. John
Chabot, M.D., Chief of Surgical Oncology at Columbia, phone (212)
305-9468."
[source: http://www.dr-gonzalez.com/clinical_pearls.htm ]
a bit is written about that therapy here, as well:
http://nccam.nih.gov/about/offices/od/directortestimony/0607 (I
first found out about this link from here:
http://cancerforums.net/viewtopic.php?t=3247 )